Cargando…

Mechanism of histone deacetylases in cardiac hypertrophy and its therapeutic inhibitors

Cardiac hypertrophy is a key process in cardiac remodeling development, leading to ventricle enlargement and heart failure. Recently, studies show the complicated relation between cardiac hypertrophy and epigenetic modification. Post-translational modification of histone is an essential part of epig...

Descripción completa

Detalles Bibliográficos
Autores principales:	Han, Yu, Nie, Jiali, Wang, Dao Wen, Ni, Li
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Cardiovascular Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9360326/ https://www.ncbi.nlm.nih.gov/pubmed/35958418 http://dx.doi.org/10.3389/fcvm.2022.931475

Ejemplares similares

Epigenetic Mechanism and Therapeutic Implications of Atrial Fibrillation
por: Li, Dan, et al.
Publicado: (2022)

Roles of histone acetylation sites in cardiac hypertrophy and heart failure
por: Funamoto, Masafumi, et al.
Publicado: (2023)

Mitochondria-associated endoplasmic reticulum membranes and cardiac hypertrophy: Molecular mechanisms and therapeutic targets
por: Luan, Yi, et al.
Publicado: (2022)

Role of histone deacetylase 2 and its posttranslational modifications in cardiac hypertrophy
por: Eom, Gwang Hyeon, et al.
Publicado: (2015)

Estrogen regulates histone deacetylases to prevent cardiac hypertrophy
por: Pedram, Ali, et al.
Publicado: (2013)

Toll-like receptors in cardiac hypertrophy
por: Zhang, Yanan, et al.
Publicado: (2023)

Mitochondria in Pathological Cardiac Hypertrophy Research and Therapy
por: Yang, Dan, et al.
Publicado: (2022)

Impact of polyphenols on heart failure and cardiac hypertrophy: clinical effects and molecular mechanisms
por: Hedayati, Neda, et al.
Publicado: (2023)

miR-208a in Cardiac Hypertrophy and Remodeling
por: Huang, Xing-Huai, et al.
Publicado: (2021)

Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma
por: Phimmachanh, Monica, et al.
Publicado: (2020)

Roles and Targets of Class I and IIa Histone Deacetylases in Cardiac Hypertrophy
por: Kee, Hae Jin, et al.
Publicado: (2011)

Hispidulin Attenuates Cardiac Hypertrophy by Improving Mitochondrial Dysfunction
por: Wang, Yan, et al.
Publicado: (2020)

Histone deacetylase inhibitor, CG200745, attenuates cardiac hypertrophy and fibrosis in DOCA-induced hypertensive rats
por: Lee, Eunjo, et al.
Publicado: (2016)

A high-throughput drug screening identifies luteolin as a therapeutic candidate for pathological cardiac hypertrophy and heart failure
por: Wang, Zhenya, et al.
Publicado: (2023)

Epigenetic control of signaling networks involved in interleukin-18-induced cardiac hypertrophy and its attenuation by pan-histone deacetylase inhibitors
por: Majumdar, Gipsy, et al.
Publicado: (2010)

Angiogenic Endothelial Cell Signaling in Cardiac Hypertrophy and Heart Failure
por: Gogiraju, Rajinikanth, et al.
Publicado: (2019)

Histone Deacetylases and Histone Deacetylase Inhibitors: Molecular Mechanisms of Action in Various Cancers
por: Sanaei, Masumeh, et al.
Publicado: (2019)

Histone Deacetylases in the Inflamed Intestinal Epithelium—Promises of New Therapeutic Strategies
por: Gerbeth, Lorenz, et al.
Publicado: (2021)

Histone deacetylase inhibitors as novel anticancer therapeutics
por: Walkinshaw, D.R., et al.
Publicado: (2008)

Key Player in Cardiac Hypertrophy, Emphasizing the Role of Toll-Like Receptor 4
por: Xiao, Zheng, et al.
Publicado: (2020)

The Histone Deacetylase 9 Stroke-Risk Variant Promotes Apoptosis and Inflammation in a Human iPSC-Derived Smooth Muscle Cells Model
por: Granata, Alessandra, et al.
Publicado: (2022)

Protective Effects of Thyroid Hormone Deprivation on Progression of Maladaptive Cardiac Hypertrophy and Heart Failure
por: Kerp, Helena, et al.
Publicado: (2021)

Cardiac “hypertrophy” phenotyping: differentiating aetiologies with increased left ventricular wall thickness on echocardiography
por: Ferkh, Aaisha, et al.
Publicado: (2023)

Histone Methylation Related Therapeutic Challenge in Cardiovascular Diseases
por: Yang, Yang, et al.
Publicado: (2021)

Cardiac Remodeling in Heart Failure: Role of Pyroptosis and Its Therapeutic Implications
por: Chai, Ruoning, et al.
Publicado: (2022)

Cardiac ISL1-Interacting Protein, a Cardioprotective Factor, Inhibits the Transition From Cardiac Hypertrophy to Heart Failure
por: Yan, Youchen, et al.
Publicado: (2022)

Mechanisms and Therapeutic Targets of Cardiac Regeneration: Closing the Age Gap
por: Castellan, Raphael F. P., et al.
Publicado: (2018)

TANK Promotes Pressure Overload Induced Cardiac Hypertrophy via Activating AKT Signaling Pathway
por: Pang, Yanan, et al.
Publicado: (2021)

NAP1L5 Promotes Nucleolar Hypertrophy and Is Required for Translation Activation During Cardiomyocyte Hypertrophy
por: Guo, Ningning, et al.
Publicado: (2021)

Elevated tissue inhibitor of metalloproteinase-1 along with left atrium hypertrophy predict atrial fibrillation recurrence after catheter ablation
por: Sun, Weiping, et al.
Publicado: (2022)

Lysosomal-Associated Protein Transmembrane 5 Functions as a Novel Negative Regulator of Pathological Cardiac Hypertrophy
por: Gao, Lu, et al.
Publicado: (2021)

Downregulation of PTEN Promotes Autophagy via Concurrent Reduction in Apoptosis in Cardiac Hypertrophy in PPAR α(−/−) Mice
por: Kumari, Ritu, et al.
Publicado: (2022)

Loss of m(6)A Methyltransferase METTL5 Promotes Cardiac Hypertrophy Through Epitranscriptomic Control of SUZ12 Expression
por: Han, Yanchuang, et al.
Publicado: (2022)

Tyrosine Kinase Inhibitors-Induced Arrhythmias: From Molecular Mechanisms, Pharmacokinetics to Therapeutic Strategies
por: Cheng, Mengfei, et al.
Publicado: (2021)

Spatial Heterogeneity of Cx43 is an Arrhythmogenic Substrate of Polymorphic Ventricular Tachycardias during Compensated Cardiac Hypertrophy in Rats
por: Boulaksil, Mohamed, et al.
Publicado: (2016)

FABP3 Deficiency Exacerbates Metabolic Derangement in Cardiac Hypertrophy and Heart Failure via PPARα Pathway
por: Zhuang, Lingfang, et al.
Publicado: (2021)

Novel Proteasome Inhibitors and Histone Deacetylase Inhibitors: Progress in Myeloma Therapeutics
por: Chhabra, Saurabh
Publicado: (2017)

The Roles of Cardiac Fibroblasts and Endothelial Cells in Myocarditis
por: Xuan, Yunling, et al.
Publicado: (2022)

Butyrate Histone Deacetylase Inhibitors
por: Steliou, Kosta, et al.
Publicado: (2012)

Therapeutic Strategies to Enhance the Anticancer Efficacy of Histone Deacetylase Inhibitors
por: Miller, Claudia P., et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_h0f1q8ploeifa2mp00cschrgiu